lymphoma for Autologous peripheral blood stem
Conditions
Interventions
Experimental group:With TPO
Control Group:Without TPO
Sponsors
Shanghai General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed as lymphoma with pathological evidences; 2. Patients that have indications for APBSCT and are willing to have transplantation; 3. Aged 18-60 years; 4. ECOG =3 5. Normal organ functions should satisfy: liver function: ALT, AST, TBIL= twice of the normal maximum; renal function: BUN, Cr=1.5 times of the normal maximum; cardiac function: ECG reveals no signs of acute myocardial infarction, arrhythmia, nor II or III degree of a-v blockage; heart function failure should be no more than degree II; no active rheumatic heart diseases; 6. No contraindications for chemotherapy; 7. Patients should sign the written consent before enrollment of the trial, and the written consent should consent all the contents of the trial; 8. Willing to follow the therapeutic plan, the follow-up plan and take the corresponding lab examinations.
Exclusion criteria
Exclusion criteria: 1. Contra-indications for chemotherapy; 2. Patients with severe organ impairment: including respiratory failure, heart failure of degree II and beyond, decompensated liver failure, renal failure; uncontrolled hypertention or diabetes, severe diabetic retinal disease; 3. Use of cytokines beside G-CSF within 3 weeks prior to enrollment; 4. Uncontrolled infection; 5. History of severe rhTPO allergy; 6. Women during pregnancy or lactation; 7. Patients that are participating other trials; 8. Patients with other severe acute/chronic physical or mental disorders, or with abnormal lab tests that may impair drug administration or influence the researchers evaluation, or influence the explanation about the results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| nucleated cell count;CD34+ cell count;times needed for collecting required amount of cells; | — |
Secondary
| Measure | Time frame |
|---|---|
| compliance rate;excellence rate;implantation time;RBC transfusion amount after implantation;Platelet transfusion amount after implantation;Incidence of infection during transplantation; | — |
Countries
China
Contacts
Public ContactChun Wang
Shanghai General Hospital
Outcome results
None listed